10/13/04:
Oil Prices Give Blue Chips A Crude Awakening
PAUL KANGAS: A big rebound in oil prices fueled a big
sell-off for blue chip stocks today. By the closing bell, the Dow had lost
74 points. Crude oil prices started the day lower, but then surged to
close back at Monday`s record level of $53.64 a barrel. The big concern in
the markets continues to be supplies for the upcoming winter season, which
also pushed heating oil prices to a record. Many traders think crude
prices will continue to move higher, but even if that happens, stock
experts don`t believe it will lead to a big sell-off on Wall Street.
RICHARD SCHAEFFER, HEAD OF GLOBAL ENERGY FUTURES, ABN AMRO: The sense
among the traders is that it`s going to go to $60 a barrel. I myself do
not have that feeling. I think it`s going to test a little bit and keep
trying to make new highs, but it seems to me we`re starting to get near the
top.
JAMES AWAD, PORTFOLIO MANAGER, AWAD ASSET MANAGEMENT: You shouldn`t have a
bear market even though oil is going up in price because on balance the
economy is growing. On balance earnings are growing. On balance
corporations are in terrific shape and on balance with interest rates so
low, fixed-income investments are not a compelling alternative to
equities.
So oil is a negative, but it`s not going to create a bear market.
KANGAS: No bears, just bulls early on this morning on Wall Street. That
weakness in oil prices, coupled with brokerage upgrades in Intel and Yahoo!
and an upbeat forecast from McDonald`s buoyed the blue chips. The Dow rose
about 35 points at the outset, while the NASDAQ Index jumped 20. But as
oil prices reversed course, heading up again, stocks headed down.
Nightly Business Report transcripts are available
on-line post broadcast. The program is transcribed by eMediaMillWorks.
Updates may be posted at a later date. The views of our guests
and commentators are their own and do not necessarily represent
the views of Community Television Foundation of South Florida,
Inc. Nightly Business Report, or WPBT. Information presented
on Nightly Business Report is not and should not be considered
as investment advice. Copyright (c) 2004 Community Television
Foundation of South Florida, Inc. ALL RIGHTS RESERVED. Terms
of use.
10/13/04:
Kim Wallace Lehman Brothers` Chief Political Strategist On The Road To The White House
LINDA O`BRYON: Polls show November`s presidential election is a statistical dead
heat, with President Bush holding a lead of just 1.5 percent over
challenger John Kerry. Tonight`s last of three debates is also the last
and best chance for both sides to change that balance. As we continue
along the road to the White House, tonight Washington bureau chief Darren
Gersh gets some insight on the race from Lehman Brothers` chief political
strategist Kim Wallace.
DARREN GERSH, NIGHTLY BUSINESS REPORT CORRESPONDENT: As George Bush and
John Kerry head into their final debate, one trend worth noting involves
the man who will not be on stage tonight. Ralph Nader appears to be least
important in the states that matter most. Lehman Brothers chief political
strategist Kim Wallace says it`s one of the key trends of the closing weeks
of the campaign.
KIM WALLACE, POLITICAL ANALYST, LEHMAN BROTHERS: In the 14 to maybe 16
states that are going to matter, Nader in more than half of them is only
getting one or 2 percent of the vote and no higher than 3 percent of the
vote. I think most of those voters are going to split one way or another
come election day. And then the second is the tremendous swing in
undecided voters, both in their number, through most of the year, through
the end of the summer, it was estimated undecided voters were no more than
3 to 5 percent of the electorate. That`s as high as 9 to 11 percent now.
Most of those people have been trending toward Kerry, particularly after
the first debate almost two weeks ago.
GERSH: Unlike previous debates, tonight`s will focus solely on domestic
issues and Wallace expects one issue to dominate.
WALLACE: I think the one that will get the most attention will be jobs, but
I think the most important issue for the economy going forward splits in
two, that is who is going to do the spending to generate growth, the
concerns about the consumers, given the debt rise in the household,
households now have about 115 percent debt to disposable income, and the
other side is business spending, cap ex. Will we see capital expenditures
increase in 2005 sufficient to make up for any falloff in the consumer
spending? Obviously remains to be seen, but it`s those pieces of the puzzle
that I think will matter most in the economy.
GERSH: It also seems that in a presidential election there is the public
agenda that`s getting talked about and then there`s the agenda that
everybody in Washington knows is waiting for the next president, no matter
who is elected. So what`s going to be on the next president`s plate that
they`re going to have to deal with that we`re not hearing about in the
campaign?
WALLACE: That`s actually I think a good question because in my view the
ready-made agenda that you refer to is likely to dominate the next
president, irrespective of who wins. Iraq and national security will top
the list. The challenges there are well known. I think fiscal policy is
going to continue to poke its head through. That will become more
important when we see the effects of what I consider to be run away fiscal
policy in the markets, which we haven`t seen to date. The 10-year bond
yield continues to bounce between 4.18 and 4.10. I think you`re going to
have to get a lot closer to 5 before Washington feels pressure from the
markets to do anything about fiscal policy.
GERSH: It sounds like the next president is going to have a tough agenda
waiting for them, tough fiscal policy, tough foreign policy, not a lot of
wiggle room.
WALLACE: That`s right. When you throw in the other domestic issues of
pensions, both the private and public pension funds are viewed to be in
trouble. Obviously the U.S. is not in as bad a shape relatively speaking
as some of its other major G-10 competitors, but nonetheless, the private
pension system on the defined benefit side has about a $400 billion gap
between obligations and assets on the net present value basis.
The Pension Benefit Guarantee Corporation closed the year with about a $15
billion deficit, the fiscal year `04 and they`ve got on the books about
another $85 billion in obligations from companies that are now junk bond
rated or worse. You go into health care, both in terms of Medicare
spending and the cost premium increases along with increases in benefits
coming in `06, there`s a lot for Washington and the next president to chew
on before they get to their preferred agenda.
GERSH: Kim Wallace, political analyst with Lehman Brothers, thanks a lot,
Kim.
WALLACE: Thank you, Darren.
Nightly Business Report transcripts are available
on-line post broadcast. The program is transcribed by eMediaMillWorks.
Updates may be posted at a later date. The views of our guests
and commentators are their own and do not necessarily represent
the views of Community Television Foundation of South Florida,
Inc. Nightly Business Report, or WPBT. Information presented
on Nightly Business Report is not and should not be considered
as investment advice. Copyright (c) 2004 Community Television
Foundation of South Florida, Inc. ALL RIGHTS RESERVED. Terms
of use.
10/13/04:
One On One With Ray Gilmartin, Chairman & CEO, Merck
LINDA O`BRYON: Merck and Company went public today with more information on how
it found trouble with its arthritis drug Vioxx and why it was pulled off
the market on September 30. At a news conference in New York City, the
company`s head of research laid out a timeline for Merck`s realization that
Vioxx was problematic. Peter Kim says it was late last month when the
company had definitive data showing that with long-term use, patients
taking Vioxx had double the risk of heart attack and stroke as those taking
a placebo.
Earlier today, I talked with Merck`s chief executive officer, Ray Gilmartin
about the problems with Vioxx. I began by asking him if he has learned
anything from the scientific community that would have caused him to do
anything differently.
RAY GILMARTIN, CHAIRMAN AND CEO, MERCK: No, not at all. I think the
overwhelming response from the scientific community is that we did follow
the responsible course of action. We have heard from some, some patients
and some physicians, that they benefited uniquely or had patients that
benefited uniquely from the product and expressed disappointment that we
made the decision to voluntarily withdraw it. But the overwhelming
response was that we did the right thing. We did the responsible thing and
we did it promptly.
O`BRYON: NIGHTLY BUSINESS REPORT recently interviewed an attorney who
filed a lawsuit against Merck two years ago alleging that the company knew
Vioxx caused heart attacks and strokes two-and-a-half years ago. How will
you counter those types of claims?
GILMARTIN: Well, I would point to the fact that all of the data that we had
under the randomized clinical control trials, which is the only way to
really understand the effect of treatment, that`s testing the hypothesis.
All the data that we had on extensive studies, 28,000 patients, patients
with cardiovascular risk factors, all showed no difference between placebo
and Vioxx or between Vioxx and commonly used (INAUDIBLE) such as ibuprofen
or (INAUDIBLE). So that all of the data that we had available to us in
these controlled settings suggested or showed or demonstrated that there
was no difference between Vioxx and placebo.
O`BRYON: Mr. Gilmartin, what`s the future of the Merck product, Arcoxia, an arthritis drug that`s already available in countries outside the
U.S.? Do you expect to have a decision from the FDA on its use here by the
end of this month?
GILMARTIN: Well, that`s the earliest date that we`d expect to hear from the
FDA. They usually meet those kinds of timetables. So at this point, we
really can`t speculate how the FDA is going to react to this. We`ve, of
course, provided them with the data around Vioxx when we announced to them
or went down to see them to tell them that we were voluntarily withdrawing
the drug and submitted the data to them at that time. At this point we
can`t really speculate how they`re going to react to all of this.
O`BRYON: And finally, it`s been widely reported that Merck directors have
been reviewing outside recruiters in the search for your successor. Do you
have any plans to change your planned retirement for 2006?
GILMARTIN: No not at all. And I think most importantly the directors have
no plans to change my retiring dates. The September board meeting, which
was also the board meeting in which we described to the directors what had
been learned through the approved trial, this is the trial with the
demonstrated cardiovascular risk after 18 months, that was the first time
they really learned that -- of our decision to withdraw the drug because we
had just gotten the data a few days before. The meeting with the outside
search firms was regularly scheduled and is part of a very deliberate and
orderly process undertaken by the board to provide for my succession. So
that was on time. It was scheduled and shouldn`t indicate -- doesn`t
indicate anything at all about change in timing.
O`BRYON: From a corporate standpoint, this has to be a very difficult time
for you personally. What lessons have you learned about crisis management
from this entire situation?
GILMARTIN: Well, I think that the principle that we`ve been following here
is to, first of all, once having discovered that there was an increased
risk beginning after 18 months, was to act quickly and decisively to make
the decision to withdraw the drug voluntarily. So I think that quick
disclosure, acting decisively and take action. In addition to that, we
continue to be available. I`m personally available to talk to a number of
audiences in different settings, media and so on, in order to really
continue to explain what happened, why we took the course of action that we
did, to help people understand and have the right context for understanding
our actions.
O`BRYON: Thank you very much. Raymond Gilmartin.
GILMARTIN: Thank you.
Nightly Business Report transcripts are available
on-line post broadcast. The program is transcribed by eMediaMillWorks.
Updates may be posted at a later date. The views of our guests
and commentators are their own and do not necessarily represent
the views of Community Television Foundation of South Florida,
Inc. Nightly Business Report, or WPBT. Information presented
on Nightly Business Report is not and should not be considered
as investment advice. Copyright (c) 2004 Community Television
Foundation of South Florida, Inc. ALL RIGHTS RESERVED. Terms
of use.
10/13/04:
"The Big Squeeze"-How To Survive
LINDA O`BRYON: This is turning out to be a challenging growing season for
Florida`s citrus industry. A perfect storm of hurricane damage, low prices
and international competition is forcing producers to change how they do
business. In the second part of our series "the big squeeze," Jeff Yastine
looks at how one grove owner is adapting to survive.
JEFF YASTINE, NIGHTLY BUSINESS REPORT CORRESPONDENT: These are some of the
southernmost commercial orange groves you`re likely to find in the United
States. Located just north of the Florida everglades, the groves are
controlled by Southern Gardens Citrus, a unit of agribusiness giant U.S.
Sugar. Three million citrus trees, 32,000 acres and 42 million gallons of
OJ produced annually. That`s a lot of juice.
Despite the company`s size and its thousands of acres of orange groves,
Southern Gardens was not spared the same problems affecting all the other
Florida citrus growers-- namely oversupply and record low prices. So,
Southern Gardens decided to move away from being just a bulk grower of a
low-priced commodity. The result? This, the company`s own packaging plant,
where it processes oranges into its own not-from-concentrate juice
product.
Previously, Southern Gardens would have sold its loads of oranges to an
industry heavyweight like Tropicana. Now, it hopes to gain a small share
of Tropicana`s own market by packaging not-from-concentrate products for
private-label customers like Kroger and Walgreen`s.
RODNEY LIDDLE, CEO, SOUTHERN GARDENS CITRUS: We believe that there`s a lot
of room for private-label, not-from-concentrate to grow in the United
States. There are very few players who are vertically integrated and able
to bring that value to the marketplace. We`re able to do that. We`re a
grower. We`re a processor. We`re a storer and now we`re a packager. We`re
the only company in Florida that`s able to deliver all of those
attributes.
YASTINE: Even after damage from the summer`s hurricanes took out 20 percent
of the state`s crop, prices for wholesale orange juice are still only about
where they were 20 years ago, too much supply and too little demand.
Industry experts say that`s partly due to the low-carbohydrate diet trend.
But there are other reasons, as well.
ANDREW LEVIGNE, FLORIDA CITRUS MUTUAL: You just have constant competition
for that share of the consumer`s stomach, as they call it, or share of the
consumer`s thirst to fill. Whether its juice drinks that aren`t 100
percent, like orange juice, or whether it`s soft drinks or other products,
the consumer is constantly barraged with new products to try every year.
YASTINE: To compete with all those new products, Southern Gardens` Liddle
says his company and the Florida OJ industry will need to pay a lot closer
attention to the consumer market.
LIDDLE: We need to be innovative with respect to our product offerings,
both in terms of sizes, shape, convenience. Second, we need to provide
products that consumers want. You`ve seen two of the brands come out with
a 50 percent juice product recently. We need to do that. We need to be
responsive to what consumers want.
YASTINE: With its own packaging line now up and running, Southern Gardens
Citrus stands ready to provide those OJ products to store shelves. Jeff
Yastine, NIGHTLY BUSINESS REPORT, Clewiston, Florida.
Nightly Business Report transcripts are available
on-line post broadcast. The program is transcribed by eMediaMillWorks.
Updates may be posted at a later date. The views of our guests
and commentators are their own and do not necessarily represent
the views of Community Television Foundation of South Florida,
Inc. Nightly Business Report, or WPBT. Information presented
on Nightly Business Report is not and should not be considered
as investment advice. Copyright (c) 2004 Community Television
Foundation of South Florida, Inc. ALL RIGHTS RESERVED. Terms
of use.
10/13/04:
"Money File"-The High Price of Living Longer
LINDA O'BRYON: In tonight`s money file, hoping for the best but preparing for the worst
when it involves your health. Here`s Terry Savage, author of the "Savage
Truth on Money."
TERRY SAVAGE, AUTHOR, "THE SAVAGE TRUTH ON MONEY": There`s great news:
we`re living longer. There`s a downside: it`s going to cost more. We all
hope to lead long and healthy lives thanks to the wonders of modern
science. Yet experts predict that one of every two people living past age
65 will eventually need some form of assistance with the basic activities
of daily living.
Today, about seven million people reside in nursing homes. In 15 years,
the boomers will start to crowd in. A new survey shows that the average
cost of just one year in a nursing facility has risen to $70,000. When it
comes to making your money disappear, the need for long-term care could be
far more disastrous to your retirement planning than the next bear market.
Yet just 9.1 million people purchase long-term care insurance policies last
year. Perhaps it`s because we just don`t like to think about going into a
nursing home or visiting our parents there.
The latest generation of long-term care insurance policies provides
benefits for home health care and for assisted living facilities. They
offer inflation protection, as well. The younger you start, the lower the
cost of these insurance policies. Remember: Medicare and supplements don`t
cover the cost of long-term custodial care and state Medicaid programs to
cover the impoverished are already overwhelmed by the cost of caring for
today`s seniors. Baby boomers, this is a wake-up call. You insure your
home and your car against risk. Now it`s time to insure your retirement
plans against the risk of meeting long-term care. I`m Terry Savage.
Nightly Business Report transcripts are available
on-line post broadcast. The program is transcribed by eMediaMillWorks.
Updates may be posted at a later date. The views of our guests
and commentators are their own and do not necessarily represent
the views of Community Television Foundation of South Florida,
Inc. Nightly Business Report, or WPBT. Information presented
on Nightly Business Report is not and should not be considered
as investment advice. Copyright (c) 2004 Community Television
Foundation of South Florida, Inc. ALL RIGHTS RESERVED. Terms
of use.
10/13/04:
Paul Kangas' "Stocks In The News"
PAUL KANGAS: No bears, just bulls early on this morning on Wall Street. That
weakness in oil prices, coupled with brokerage upgrades in Intel and Yahoo!
and an upbeat forecast from McDonald`s buoyed the blue chips. The Dow rose
about 35 points at the outset, while the NASDAQ Index jumped 20. But as
oil prices reversed course, heading up again, stocks headed down.
The Dow industrial average finally closed down 74.85 points at 10,002.33.
The NASDAQ Composite lost only 4 2/3 points ending at 1,920.53. Standard &
Poor`s 500 down 8.19, ending at 1113.65. Treasuries showed some modest
gains. The 10-year note rose 12/32, pushing the yield down to 4.06
percent.
The most active big board issue on 23 million shares, Accenture Ltd (ACN)
down $2.65. The management consulting firm reported higher fourth quarter
earnings of $0.30, up from $0.25 a year ago. But it seems first quarter
earnings dropping to $0.28 to $0.31, well below the Street estimate of
$0.32. It also dropped full year earnings estimates for next year by $0.03,
down to $1.36 a share. But the company did say it`s going to buy back up to
$3 billion of its stock.
Pfizer (PFE) $0.31 loss.
Calpine (CPN) dropped $0.18.
And there you see Merck & Co (MRK) down $0.78.
Lucent Technology (LU) moved up $0.04, fifth in big board volume.
Nokia (NOK) rising $0.18.
Texas Instruments (TXN) rebounding $0.43 from recent losses.
General Electric (GE) down $0.31.
Citigroup (C) fell $0.69.
And ExxonMobil (XOM) down $0.89, tenth in big board volume.
McDonald`s (MCD), one of the stars in the Down today, up $1.31. The company
says its preliminary estimate of third quarter earnings is $0.61, way up
from $0.18 a year ago and $0.12 above the Street estimate. Those earnings
are due out next Tuesday, the 19th.
Union Pacific (UNP) down $1.18. UBS Securities downgraded it from "buy" to
just a "neutral" rating.
And then Harley-Davidson (HD) dropped $1.02. Third quarter earnings were
higher, $0.77, up from $0.62 a year ago, $0.02 above the Street estimate
but Harley says U.S. motorcycle sales in the third quarter fell 9.8
percent.
HCA Inc. (HCA) down $1.19. The company warned its third quarter earnings
will be about $0.48 at best. The Street estimate is $0.51, but it also said
it`s going to have a big stock buy back, $2.5 billion worth of it.
Nucor (NUE) the steel company, off $4.49. Soleil Securities downgraded it
from "hold" to "sell." This had a negative impact on the whole steel group.
We see a lot of the major stocks dropping.
AK Steel Holding (AKS) just a fractional loss.
But Oregon Steel (OS) and US Steel (X) off well over $1 each.
Freeport-McMoran Copper & Gold (FCX) not just the steels were hurt, but a
lot of the precious and basic metal stocks. On this case, Freeport was
downgraded by Prudential from "overweight" to "neutral."
And we see a sector board, Alcoa (AA), the aluminum down.
And Anglogold Ashanti (AU) off $1.10.
But losses in the nickel steel, Inco Ltd (N) then Phelps Dodge (PD) which
of course is a copper producer.
Dana Corp (DCN), the auto parts maker, down $1.76. Company cut its 2004
earnings estimate from $1.90 down to $1.60 to $1.65 because of higher steel
costs. Merrill Lynch downgraded the stock from "buy" to "neutral."
And then Jones Apparel (JNY) down $2.73. The company cut its third quarter
estimate, which on the Street is $0.85. Says it`s only going to earn $0.75
to $0.77, cited soft consumer confidence and a weak employment picture.
And finally Borders Group (BGP) off $2.29. The company sees a third
quarter loss of $0.01 to $0.03 and said so far the current quarter of same
store sales had dropped 1.9 percent from last year.
Intel (INTC) topped the active list with a $0.71 gain.
Then Yahoo! (YHOO) up $0.73. Both of those stocks were upgraded by various
brokerages.
Google (GOOG) up 3 1/2 points. Soleil Securities upgraded it from "sell" to
"hold."
Cisco Systems (CSCO) a $0.30 loss.
No change in Microsoft (MSFT) today.
eBay (EBAY) up $1.07.
Research in Motion (RIMM) gained $0.95.
Applied Materials (AMAT) $0.23 rise.
And Apple Computer (AAPL) up $1.46. After the close, Apple reported fourth
quarter earnings $0.26, more than double $0.12 last year, gave an upbeat
first quarter estimate of $0.42. In the last quarter, the company said it
sold 2 million iPod music players, so it really had a very good quarter.
Oracle (ORCL) was down $0.16, tenth in volume on NASDAQ.
And then we had a new issue today, Huron Consulting Group (HURN). This was
5 million shares offered to the public at 15 1/2, opened at 18 1/2, the
high of the day $20.01, backed off just a touch from there.
Finally, Lincare Holdings (LNCR) down, up $5.68, provides respiratory
therapy and the stock was boosted by a Medicare proposal to increase fees
for such services. UBS Securities also upgraded it from "neutral" to
"buy."
And those are the stocks in the news tonight.
10/13/04:
Market Stats
NET PERCENT
CLOSE CHANGE CHANGE
DOW CLOSE 10002.33 -74.85 - .7
HIGH 10127.17
LOW 9957.79
NASDAQ COMP. 1920.53 -4.64 -.2
HIGH 1948.01
LOW 1914.46
VOLUME 1,549.0
PREVIOUS 1,320.1
UP VOLUME 391.1
DOWN VOLUME 1,139.6
DOW TRANSPORTS 3282.43 -56.55 - 1.7
DOW UTILITIES 299.13 -3.14 - 1.0
CLOSING TICK +146
S&P 500 1113.65 -8.19 - .7
S&P 100 535.48 -3.74 - .7
MIDCAP 400 587.43 -5.03 - .9
REUTERS/CRB 282.56 -1.86 - .7
NYSE COMPOSITE 6556.53 -53.18 - .8
VALUE LINE 357.48 -3.17 - .9
RUSSELL 2000 569.42 -7.29 - 1.3
DJW 5000 10881.01 -81.95 - .8
U.S. TREASURIES
5-YEAR NOTE 3.375%
Oct. 15,2009 100 11/32 +9/32 + 3.30
10-YEAR NOTE 4.25%
Aug. 15,2014 101 17/32 +12/32 + 4.06
30-YEAR NOTE 5.375%
Feb. 15, 2031 107 19/32 +12/32 + 4.86
LEHMAN BROS.
LONG BOND INDEX 1765.42 +3.32
DOW CLOSE 10002.33 -74.85 - .7
ADVANCES 1081
DECLINES 2223
NEW HIGHS 105
NEW LOWS 43
NET PERCENT
NYSE MOST ACTIVES 4PM CLOSE CHANGE CHANGE
ACN Accenture Ltd 23.93 -2.65 -10.0
PFE Pfizer 29.55 -.31 -1.0
CPN Calpine 2.33 -.18 -7.2
MRK Merck & Co 30.07 -.78 -2.5
LU Lucent Tech 3.42 +.04 +1.2
NOK Nokia 13.98 +.18 +1.3
TXN Texas Instrument 21.73 +.43 +2.0
GE GE 33.71 -.31 -.9
C Citigroup 44.11 -.69 -1.5
XOM Exxon Mobil 48.48 -.89 -1.8
NASDAQ CLOSE 1920.53 - 4.64 - .2
VOLUME 1,788.4
PREVIOUS 1,523.6
ADVANCES 1195
DECLINES 1876
NASDAQ ACTIVES
INTC Intel 20.99 +.71 +3.5
YHOO Yahoo! 34.96 +.73 +2.1
GOOG Google 140.90 +3.50 +2.6
CSCO Cisco Systems 18.86 -.30 -1.6
MSFT Microsoft 28.03 unch. unch.
EBAY eBay 94.56 +1.07 +1.1
RIMM Rsch In Motion 77.92 +.95 +1.2
AMAT Applied Matl 16.39 +.23 +1.4
AAPL Apple Computer 39.75 +1.46 +3.8
ORCL Oracle 11.99 -.16 -1.3
AMEX CLOSE 1273.40 - 3.56 - .3
INDEX SHARES
DIA DIAMONDS TRUST 100.08 -.91 -.9
QQQ NASDAQ 100 35.65 -.09 -.3
SPY S&P DEP.RECEIPTS 111.54 -.99 -.9
STOCKS IN THE NEWS
Display Name
MCD McDonald's 28.86 +1.31 +4.8
UNP Union Pacific 60.33 -1.18 -1.9
HDI Harley-Davidson 58.72 -1.02 -1.7
HCA HCA Inc 36.18 -1.19 -3.2
NUE Nucor 88.61 -4.49 -4.8
AKS AK Steel Holding 9.40 -.79 -7.8
OS Oregon Steel 15.15 -1.52 -9.1
X US Steel 35.68 -1.78 -4.8
FCX Frprt-McMoRan C&G 36.40 -3.43 -8.6
AA Alcoa 32.19 -1.00 -3.0
AU Anglogold Ashanti 36.17 -1.10 -3.0
N Inco Ltd 35.26 -2.24 -6.0
PD Phelps Dodge 83.10 -8.64 -9.4
DCN Dana Corp 14.84 -1.76 -10.6
JNY Jones Apparel 33.57 -2.73 -7.5
BGP Borders Group 22.11 -2.29 -9.4
HURN Huron Consulting 18.90 +3.40 +21.9
LNCR Lincare Holding 36.99 +5.68 +18.1
|
